I’ve been diving into the nuances of CRISPR applications, particularly its limitations in human studies. Recently, I came across several cases where off-target effects have significantly impacted experimental outcomes. I wonder how others are addressing these challenges in their research and what methodologies are being employed to mitigate such risks. Any insights?